Showing 1651-1660 of 4063 results for "".
- Ashvattha Therapeutics to Present Phase 2 DME and Wet AMD Datahttps://modernod.com/news/ashvattha-therapeutics-to-present-phase-2-dme-and-wet-amd-data/2482846/Ashvattha Therapeutics announced it will present new data focusing on previously reported phase 2 clinical data on migaldendranib, its investigational subcutaneous therapy for diabetic macular edema (DME) and wet age-related macular degeneration (AMD), which could offer a
- Aurion Biotech Announces Completion of Enrollment in Phase 1/2 Clinical Trialhttps://modernod.com/news/aurion-biotech-announces-completion-of-enrollment-in-phase-12-clinical-trial/2482253/Aurion Biotech announced it has completed dosing of all subjects in its phase 1/2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. AURN001 is a combination cell therapy product (biologic/d
- Ocugen Completes Dosing in Phase 1/2 Trial of OCU410 for Geographic Atrophyhttps://modernod.com/news/ocugen-advances-armada-trial-of-ocu410-to-treat-patients-with-geographic-atrophy/2482238/Ocugen announced dosing is complete in the second cohort of its phase 1/2 ArMaDa trial of OCU410, an adeno-associated viral vector 5 human RORA (AAV5-hRORA) gene therapy being developed for geographic atrophy (GA). Up to 13
- OcuTerra Fails Phase 2 DR:EAM Trial Evaluating Nesvategrast for Diabetic Retinopathyhttps://modernod.com/news/ocuterra-fails-phase-2-dream-trial-evaluating-nesvategrast-for-diabetic-retinopathy/2482163/OcuTerra Therapeutics announced topline results from its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial of nesvategrast (OTT166), a novel, selective RGD integrin inhibitor developed as an eye drop. The clinical trial did not meet its primary or key secondary ef
- Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRShttps://modernod.com/news/annexon-to-report-archer-phase-2-trial-results-in-geographic-atrophy-at-asrs/2481746/Annexon announced the company will present results from the ongoing ARCHER phase 2 trial in patients with geographic atrophy (GA) at the American Society of Retina Specialists (ASRS) 2023 annual meeting taking place July 28-August 1,
- Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetingshttps://modernod.com/news/ocuphire-announces-apx3330-phase-2-data-presentations-at-retina-meetings/2481416/Ocuphire Pharma announced two presentations featuring efficacy and safety results from the company’s recently completed ZETA-1 phase 2 trial of oral APX3330 in diabetic retinopathy (DR) at two medical meetings in February. Peter Kaiser, MD, Professor of Ophthalmology at the C
- Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucomahttps://modernod.com/news/nicoxs-ncx-470-dolomites-phase-2-results-published-in-journal-of-glaucoma/2480758/Nicox announced that the results from its Dolomites phase 2 clinical trial of NCX 470 in patients with open-angle glaucoma or ocular hypertension have been published online by the Journal of Glaucoma. The publication “A R
- AxeroVision Announces Phase 2 Results for Dry Eye Disease Creamhttps://modernod.com/news/axerovision-announces-phase-2-results-for-axr-270-for-treatment-of-dry-eye-disease-associated-with-mgd/2479478/AxeroVision announced positive results from a phase 2 investigational treatment of AXR-270, the company’s novel, proprietary, once-daily glucocorticoid cream, in patients with signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD). I
- Alcon’s ORA System Reaches 2 Million Caseshttps://modernod.com/news/alcons-ora-system-reaches-2-million-cases/2479303/Alcon announced its Optiwave Refractive Analysis (ORA) intraoperative aberrometer system has reached 2 million cases worldwide. This milestone signifies an important leap forward in cataract surgery by delivering greater accuracy than preoperative calculation methods alone. The ORA Syste
- Visus Therapeutics Initiates Phase 2 Clinical Trial of Brimochol for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-initiates-phase-2-clinical-trial-of-brimochol-for-the-treatment-of-presbyopia/2479013/Visus Therapeutics announced the commencement of its phase 2 clinical trial of Brimochol topical ophthalmic solution under investigation for the treatment of presbyopia. Brimochol is a proprietary pupil-modulating eye drop that combines two well-studied, FDA-approved pharmaceuticals: carb